Analysts at Barclays initiated coverage on Momenta Pharmaceuticals, Inc. MNTA with a Equal-weight rating. The target price for Momenta Pharmaceuticals is set to $22. Momenta Pharmaceuticals shares closed at $17.70 on Friday.
Cowen & Company initiated coverage on Myokardia Inc MYOK with a Outperform rating. The target price for Myokardia is set to $24. Myokardia shares closed at $11.83 on Friday.
Analysts at Morgan Stanley initiated coverage on Himax Technologies, Inc. (ADR) HIMX with a Overweight rating. The target price for Himax Technologies is set to $8.50. Himax Technologies shares closed at $7.34 on Friday.
JP Morgan initiated coverage on Blackstone Group LP BX with a Neutral rating. The target price for Blackstone Group is set to $40. Blackstone Group shares closed at $31.18 on Friday.
Analysts at Credit Suisse initiated coverage of Myokardia Inc MYOK with a Outperform rating. The target price for Myokardia is set to $18. Myokardia shares closed at $11.83 on Friday.
Barclays initiated coverage of Coherus Biosciences Inc CHRS with a Overweight rating. The target price for Coherus Biosciences is set to $46. Coherus Biosciences shares closed at $27.61 on Friday.
BTIG Researchinitiated coverage on Match Group Inc MTCH with a Sell rating. The target price for Match Group is set to $11. Match Group shares closed at $15.20 on Friday.
Analysts at Guggenheim Securities initiated initiated coverage on Revance Therapeutics Inc RVNC with a Buy rating. The target price for Revance Therapeutics is set to $55. Revance Therapeutics shares closed at $35.31 on Friday.
Analysts at Oppenheimer initiated coverage on Adesto Technologies Corp IOTS with a Outperform rating. The target price for Adesto Technologies is set to $8. Adesto Technologies shares closed at $5.55 on Friday.
Analysts at HSBC initiated coverage on Copa Holdings, S.A. CPA with a Buy rating. The target price for Copa Holdings is set to $75. Copa Holdings shares closed at $54.54 on Friday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in